Current practice in proton therapy delivery in adult cancer patients across Europe.

Tambas, Makbule; van der Laan, Hans Paul; Steenbakkers, Roel J H M; Doyen, Jerome; Timmermann, Beate; Orlandi, Ester; Hoyer, Morten; Haustermans, Karin; Georg, Petra; Burnet, Neil G; Gregoire, Vincent; Calugaru, Valentin; Troost, Esther G C; Hoebers, Frank; Calvo, Felipe A; Widder, Joachim; Eberle, Fabian; van Vulpen, Marco; Maingon, Philippe; Skóra, Tomasz; ... (2022). Current practice in proton therapy delivery in adult cancer patients across Europe. Radiotherapy and oncology, 167, pp. 7-13. Elsevier 10.1016/j.radonc.2021.12.004

Preview

Text 1-s2.0-S0167814021090484-main.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (1MB) | Preview

BACKGROUND AND PURPOSE

Major differences exist among proton therapy (PT) centres regarding PT delivery in adult cancer patient. To obtain insight into current practice in Europe, we performed a survey among European PT centres.

MATERIALS AND METHODS

We designed electronic questionnaires for eight tumour sites, focusing on four main topics: 1) indications and patient selection methods; 2) reimbursement; 3) on-going or planned studies, 4) annual number of patients treated with PT.

RESULTS

Of 22 centres, 19 (86%) responded. In total, 4233 adult patients are currently treated across Europe annually, of which 46% consists of patients with central nervous system tumours (CNS), 15% head and neck cancer (HNC), 15% prostate, 9% breast, 5% lung, 5% gastrointestinal, 4% lymphoma, 0.3% gynaecological cancers. CNS are treated in all participating centres (n = 19) using PT, HNC in 16 centres, lymphoma in 10 centres, gastrointestinal in 10 centres, breast in 7 centres, prostate in 6 centres, lung in 6 centres, and gynaecological cancers in 3 centres. Reimbursement is provided by national health care systems for the majority of commonly treated tumour sites. Approximately 74% of centres enrol patients for prospective data registration programs. Phase II-III trials are less frequent, due to reimbursement and funding problems. Reasons for not treating certain tumour types with PT are lack of evidence (30%), reimbursement issues (29%) and/or technical limitations (20%).

CONCLUSION

Across European PT centres, CNS tumours and HNC are the most frequently treated tumour types. Most centres use indication protocols. Lack of evidence for PT and reimbursement issues are the most reported reasons for not treating specific tumour types with PT.

Interest & Impact

Downloads

127 since deposited on 27 Dec 2022
69 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item